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Organophosphates are registered for use as pesticides in the agricultural 
sector in South Africa (SA). Unfortunately, many products are sold 
illegally for use as domestic rodenticides, where young children may 
be at risk of accidental exposure.[1] In SA, data on organophosphate 
pesticide poisoning (OPP) in children are scarce.[2-5] A review of cases 
(2003 - 2008) seen at Red Cross War Memorial Children’s Hospital, 
Cape Town, SA, showed that of 311 pesticide incidents, 203 were 
caused by cholinergic pesticides (organophosphates and carbamates), 
leading to a median hospital stay of 3 days for symptomatic patients 
(n=195/203).[2] Of these cholinergic incidents, 120 (59%) patients 
required admission to a high-care or intensive care unit (ICU); 5 of 
them died. The severity of presentation of this cohort shows that 
more than half of paediatric patients may require respiratory support, 
including assisted ventilation, in addition to the administration of 
atropine for control of muscarinic symptoms. Adequate knowledge of 
appropriate ventilatory resuscitation and early medical management 
for patients with OPP is essential for medical practitioners providing 
emergency care. We describe a case of severe OPP with prolonged 
apnoea and paralysis, most likely due to suboptimal atropinisation 
and the use of suxamethonium for airway intubation. 
Case report
A 17-month-old well-grown boy was found acutely ill at home. He 
was vomiting, sweating, drowsy and breathing with difficulty. In the 
morning, his mother had put out rat poison mixed with rice and left 
the boy in the care of his 12-year-old sibling. 
The child was rushed to the local community health centre. On 
arrival, he had a respiratory rate (RR) of 30 breaths per minute, 
oxygen saturation levels of 100%, heart rate (HR) of 137 bpm, and 
was drowsy with pinpoint pupils and bronchorrhoea. A diagnosis 
of presumed OPP was made. He was given an intravenous (IV) 
atropine test dose of 0.01 mg/kg. At 5 - 10-minute intervals further 
bolus doses of 0.2 mg, 0.2 mg, 0.2 mg and 0.3 mg were administered 
intravenously. The child showed some response to atropine with 
tachycardia and clearing of secretions, but still had pinpoint pupils. 
While awaiting the ambulance for transfer to the referral hospital, his 
oxygen saturation decreased to 85% and the decision was taken to 
intubate and ventilate him. Rapid sequence induction was performed 
using IV midazolam 0.2 mg (0.02 mg/kg) and suxa metho nium 20 mg 
(1.7 mg/kg); he improved with manual ventilation with a self-inflating 
bag and 40% oxygen. 
The patient was tranferred by ambulance on a transport ventilator 
and with an atropine infusion (0.017 mg/kg/h). He remained sweaty, 
had pinpoint pupils and was noted to have sudden reductions in 
HR – from 186 to 95 bpm. Although he had bilateral crepitations on 
chest auscultation, he maintained oxygen saturation levels of 98% 
throughout his transfer. No further atropine bolus doses were given 
en route to the referral hospital. 
On arrival at the receiving hospital, 2 hours after initiating medical 
resuscitation, he was assessed as being severely ill, with an HR of 
97 bpm, blood pressure of 153/70 mmHg, pinpoint pupils, some 
oral secretions, severe bilateral crepitations and an oxygen saturation 
level of 62%, despite an ongoing atropine infusion. Arterial blood gas 
showed: pH 6.9, pCO2 11.1 kPa, pO2 8.0 kPa, bicarbonate 12.6 mmol/L 
and base excess ˗13.9 mmol/L. His oxygen saturation improved to 
100% after manual ventilation with a self-inflating bag and 40% oxygen. 
He was given IV Ringer’s lactate solution 120 mL and further 
IV atropine bolus doses of 0.2 mg and 0.4 mg. The clinical notes 
indicated an inadequate response to atropine, as his pupils remained 
pinpoint, but did not report on the clearing of secretions in the lungs. 
Additional medical treatment included IV ceftriaxone 1.2 g and acy -
clo vir 240 mg for management of possible sepsis. 
The patient was taken to the ICU for a continued atropine infusion 
of 0.017 mg/kg/h and intermittent positive pressure ventilation 
(IPPV). On arrival in the ICU, he had crepitations in the left lung, 
but good air entry bilaterally. His body was washed and gastric lavage 
was performed. 
Despite receiving no ongoing sedation, the child was noted to 
be completely paralysed with gasping respirations on the ventilator 
>20 hours after receiving medical attention. He had good air entry 
bilaterally, his pupils remained pinpoint, with no reaction to light, 
and he had no spontaneous movements. His atropine infusion 
was increased to 0.02 mg/kg/h. Later that day, he started making 
spontaneous movements with flexion of the upper extremities and 
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withdrawal to painful stimuli, but there was minimal movement 
of the lower limbs and no spontaneous eye opening. At this point, 
his atropine infusion was decreased to 0.004 mg/kg/h. Overnight, 
he was given diazepam and clonidine for marked restlessness and 
the following morning his atropine infusion was again increased 
to 0.017 mg/kg/h. Almost 3 days after presenting to hospital, the 
patient became more responsive, his pupils were 3 - 4 mm and 
sluggishly reactive, and he was therefore electively extubated. He 
subsequently had mild respiratory distress with a RR of 55 breaths 
per minute, subcostal recessions, alar flaring and stridor, but 
good air entry bilaterally. The patient was given dexamethasone, 
nebulised with adrenaline, placed on continuous positive airway 
pressure (CPAP) for 1 day, with ongoing clonidine and diazepam 
for sedation, and atropine was weaned to 0.004 mg/kg/h. The 
following day his level of consciousness was assessed as 10/15 on the 
Glascow Coma Scale (GCS), his pupils were 4 - 5 mm and reactive, 
and he had good air entry bilaterally. His atropine infusion was 
discontinued and he was transferred to the general medical ward 
on nasal-prong oxygen. 
On reception in the ward, he was restless and drowsy, with 
tachypnoea, bilateral crepitations and an HR of 90 bpm. No further 
doses of atropine were administered. His sedation was stopped and 
after 2 days on nasal-prong oxygen he could breathe adequately in 
room air. 
The suspicion of OPP was confirmed by a pseudocholinesterase 
level of <1 000 U/L (laboratory reference range 4 620 - 11 500 U/L) 
on two occasions 48 hours apart. Although the rodenticide active 
ingredient was not identified by laboratory analysis, the severity 
of presentation, low pseudocholinesterase level and duration of 
symptoms suggest it was an organophosphate and not a carbamate 
pesticide; treatment would, however, have been identical for both. No 
electromyographic studies were performed. Serum salicylate levels 
were negative. His blood gas steadily improved and renal function 
was normal. His clotting parameters and liver enzymes were slightly 
deranged initially; neither required active management. The patient’s 
procalcitonin was 6.36 µg/L and a chest radiograph showed perihilar 
infiltrates more marked on the left. He developed a low-grade fever 
and Klebsiella pneumonia was cultured on a tracheal aspirate. He 
completed 7 days of IV cefotaxime and acyclovir.
Of particular mention is the patient’s protracted neurological 
recovery. In the ICU, there had been concern of a hypoxic brain 
injury due to his longer than anticipated ventilatory requirements 
and reduced movements. A computed axial tomography (CAT) brain 
scan showed subtle effacement of the superior surface sulci and basal 
cisterns only, but no cerebral oedema and no intracranial pathology. 
No abnormalities were detected in his lumbar puncture aspirate. Once 
all sedation was discontinued in the general ward, only spontaneous 
eye opening and some purposeful movements were evident, as he 
remained hypotonic with marked head lag, a weak cry and unable to 
push up or sit unsupported. He progressed slowly over a few days and 
was able to walk, albeit with an unsteady gait, on discharge. He was 
not attended to by a physiotherapist during his hospital admission. 
There is no comment on his gag reflex, but continuous nasogastric 
feeds were started when he was in the ICU; these progressed to bolus 
feeds and finally to normal eating before discharge. 
His case was reported to the City of Cape Town Health Department. 
A social worker assessed the home circumstances and his parents 
were given home safety counselling before discharge of the patient. 
Subsequent telephonic contact with the family confirmed that 
the child was ‘doing well’, but no formal neurological follow-up 
examination has been undertaken. 
Discussion
Organophosphates bind irreversibly to acetylcholinesterase and 
plasma cholinesterase, rendering them unable to cleave acetylcholine 
at pre- and postsynaptic junctions and at skeletal muscle and central 
nervous system receptors. This results in a clinical syndrome of 
cholinergic overstimulation. During the acute cholinergic crisis, 
respiratory embarrassment is due to bronchorrhoea, bronchospasm, 
respiratory muscle weakness and central nervous system depression 
with loss of central respiratory drive.[6,7] Any ongoing respiratory 
difficulty and neurological weakness may be due to delayed neurotoxic 
effects, such as intermediate syndrome,[6,8] or complications secondary 
to the acute crisis, e.g. hypoxic brain injury or aspiration.[8]
Treatment of OPP requires particular attention to supportive 
care of the respiratory, neurological and cardiovascular systems. 
Antidotes may be used; atropine provides relief of muscarinic 
and central nervous system symptoms,[8] and the clinical efficacy 
of oximes is contested as current evidence is insufficient.[9] With 
appropriate treatment, clinical reversal of symptoms in the acute 
cholinergic phase should occur within hours, but the response to and 
duration of treatment are also dependent on the route of exposure, 
amount and type of organophosphate.[10] Although thorough topical 
decontamination is required, gut decontamination (activated charcoal 
and gastric lavage) should only be done if the patient presents within 
1 - 2 hours of ingestion of a potentially life-threatening amount of 
organophosphate.[6,11] 
The case described had an atypical clinical course, as the child 
showed prolonged neuromuscular blockade and apnoea beyond 
what would be expected of the acute cholinergic crisis after 
decontamination and atropinisation. It is likely that a variety of 
mechanisms contributed to his slower than usual recovery.
A possible cause for this patient’s prolonged morbidity is 
suboptimal treatment with atropine. There was a delay in optimising 
atropinisation; static rather than incremental bolus atropine doses 
were given and once an infusion was started, only two further bolus 
doses were administered despite ongoing muscarinic symptoms. In 
moderate-to-severe OPP, the current recommendation is to double 
the dose of atropine every 5 - 10 minutes until clinical improvement 
occurs, particularly the drying of respiratory secretions, reversal 
of bronchospasm and improvement in HR and blood pressure.[6,12] 
Pupils may take a little longer to dilate. Once stabilised, an atropine 
infusion is started, calculated at an hourly rate of 10 - 20% of the 
total amount required to stabilise the patient, and titrated according 
to clinical response. Any breakthrough of muscarinic symptoms 
requires bolus doses in addition to, or even with an increase in, the 
atropine infusion.[12] Regular review of patients is critical to assess 
response to atropine. It has been shown that rapid atropinisation 
results in reduced mortality, shorter time to atropinisation, less 
atropine toxicity and less intermediate syndrome.[8,13] In severely 
poisoned patients, large quantities of atropine may be required with 
the potential to deplete the available hospital stock. Fortunately, 
atropine is inexpensive and has an 18-month expiry period. This 
more aggressive approach to atropinisation would possibly have 
contributed to a speedier recovery and even obviated the need for 
emergency intubation and ventilation in this patient. Furthermore, 
the timeous use of oximes may have aided in reversing any nicotinic 
effects such as respiratory muscle weakness, but because of the 
ongoing controversy surrounding their role in acute OPP[8,9] and their 
expense, they are rarely available or used in our setting. 
Prolonged paralysis can be associated with the use of 
suxamethonium, a depolarising muscle relaxant, which is commonly 
used for patient intubation owing to its short duration of action. 
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Both suxamethonium and the non-depolarising muscle relaxant 
mivacurium are metabolised by plasma cholinesterases;[7,14] 
therefore, their metabolism is reduced in the presence of OPP, 
resulting in an exaggerated iatrogenic paralysis. This phenomenon 
has been reported in adults[15,16] and children[17-19] with OPP and 
suxamethonium use, and may have been a contributing factor to 
this child’s prolonged apnoea. Where muscle relaxants are required 
for airway intubation in patients with OPP, depolarising agents not 
metabolised by plasma cholinesterases are preferable. 
Other causes of reduced cholinesterase activity, which can 
contribute to increased OPP severity but were not present in this 
patient, are malnutrition, liver and renal disease, malignancy, 
burns, heart disease, oral contraceptive use, pregnancy, hypo-
thyroidism, use of cholinesterase inhibitors (e.g. pyridostigmine) 
and plasmapheresis.[7,14] 
Our patient’s clinical course was not typical of an intermediate 
syndrome sometimes seen in OPP, as his respiratory function 
did not regress after initial recovery, he had generalised muscle 
weakness rather than predominantly proximal weakness, and he 
did not develop any cranial nerve palsies. It is however possible that 
any recovery period between the acute cholinergic crisis and the 
development of intermediate syndrome was masked by the prolonged 
suxamethonium-induced paralysis. Intermediate syndrome usually 
presents 1 - 4 days after apparent recovery from severe, acute OPP. 
Patients develop muscle weakness, especially of the muscles of 
respiration (including neck flexors and bulbar muscles) and proximal 
muscles, as well as cranial nerve palsies. It is thought to be owing to 
neuromuscular junction dysfunction and perhaps inadequate oxime 
therapy. Patients present with worsening respiratory function, but 
recover fully with ventilatory support.[6,7] 
A central cause for our patient’s respiratory depression may have 
been due to hypoxic brain injury. Although the CAT scan did not 
completely exclude this possibility, it is less likely, as at last contact 
the child had fully recovered with no crude cognitive impairment. 
Other options for his unusual clinical course include that he 
was homozygous for atypical plasma cholinesterase and therefore 
presented with a more severe clinical picture,[7,14] or that the 
unidentified organophosphate agent was highly lipophilic, resulting 
in ongoing toxicity. 
Conclusion
Optimising resuscitation efforts is vital in ensuring improved 
outcomes for patients with OPP. Early aggressive atropinisation with 
incremental atropine bolus doses followed by infusion improves 
outcomes and may even reduce the need for intubation and ventilation 
in patients with severe OPP. 
Where emergency airway protection is required, the weakness 
caused by OPP may obviate the need for any muscle relaxant. 
However, if a muscle relaxant is clinically needed, suxamethonium 
and mivacurium should be avoided and alternative agents be made 
available as emergency stock for such patients. Alternative muscle 
relaxants, as determined by local availability and cost, include 
rocuronium (rapid speed of onset), cisatracurium (non-organ-
dependent elimination) and vecuronium. 
Teaching points
• In patients with severe OPP, rapid atropinisation with initial 
doubling of bolus doses, followed by an atropine infusion, improves 
outcomes. Regular assessment of treatment response is required. 
• Acute respiratory failure in OPP is due to bronchorrhoea, 
bronchospasm, respiratory muscle weakness and central nervous 
system depression. 
• Suxamethonium and mivacurium for intubation should not be 
used in patients with OPP, and alternative muscle relaxants should 
be considered. Where suxamethonium has been used for airway 
management, prolonged paralysis must be anticipated.
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